RxDoctor Payments Data

Amy Coy, APRN

Family · Owensboro, KYNPI 1326564048

Payments from drug & device makers

$4,125in general payments, 2019–2025

Across 295 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$872
  • AbbVie$616
  • Lilly USA, LLC$488
  • Exact Sciences$216
  • Otsuka America Pharmaceutical, Inc.$195
  • Sunovion Pharmaceuticals Inc.$152
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,125 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$53,269
Medicare patients
270
Services billed
1,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$72,437
OzempicSemaglutide55$55,178
CaplytaLumateperone Tosylate29$24,040
JardianceEmpagliflozin56$21,808
RexultiBrexpiprazole22$21,591
XareltoRivaroxaban69$21,207
MounjaroTirzepatide19$18,357
MyrbetriqMirabegron47$17,284
Nurtec OdtRimegepant Sulfate13$16,580
JanuviaSitagliptin Phosphate34$15,010
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,642
NuedextaDextromethorphan Hbr/Quinidine14$10,885
Aripiprazole42$10,393
Breo ElliptaFluticasone/Vilanterol18$7,376
Incruse ElliptaUmeclidinium Bromide20$7,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$138$89,017248 claims
Novo NordiskOzempic$872$55,17855 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$87$27,14151 claims
Boehringer IngelheimJardiance, Jentadueto Xr$42$27,07276 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$85$24,04029 claims
Otsuka America Pharmaceutical, Inc.Rexulti$195$21,59122 claims
Lilly USA, LLCMounjaro$488$18,35719 claims
Astellas Pharma US IncMyrbetriq$64$17,28447 claims
MerckJanuvia$70$15,01034 claims
Avanir Pharmaceuticals, Inc.Nuedexta$29$10,88514 claims
AstraZenecaFarxiga$95$6,71215 claims
Sumitomo Pharma America, Inc.Gemtesa$51$6,34126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →